HC Wainwright Has Negative Outlook of BCRX FY2028 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at HC Wainwright cut their FY2028 earnings per share estimates for shares of BioCryst Pharmaceuticals in a report released on Thursday, May 7th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.29 per share for the year, down from their prior estimate of $0.39. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2029 earnings at $0.86 EPS and FY2030 earnings at $2.18 EPS.

BCRX has been the topic of several other research reports. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price on the stock. Citizens Jmp lifted their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, Wedbush dropped their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.70.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $8.77 on Monday. The company has a market capitalization of $2.23 billion, a P/E ratio of -4.93 and a beta of 0.57. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The business has a 50-day simple moving average of $9.17 and a two-hundred day simple moving average of $7.93.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 EPS.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares in the company, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Larson Financial Group LLC grew its position in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals in the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Vestmark Advisory Solutions Inc. bought a new stake in BioCryst Pharmaceuticals in the third quarter worth $81,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in BioCryst Pharmaceuticals in the fourth quarter worth $81,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.